Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Swiss Exchange  >  Novartis    NOVN   CH0012005267

NOVARTIS (NOVN)
Mes dernières consult.
Most popular
Report
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Swiss Exchange
10/16/2017 10/17/2017 10/18/2017 10/19/2017 10/20/2017 Date
84.5(c) 84.1(c) 84.65(c) 84.35(c) 84.45(c) Last
3 116 366 3 366 949 3 302 620 3 897 787 3 640 553 Volume
+0.72% -0.47% +0.65% -0.35% +0.12% Change
More quotes
Financials ($)
Sales 2017 48 803 M
EBIT 2017 11 558 M
Net income 2017 7 295 M
Debt 2017 17 704 M
Yield 2017 3,30%
Sales 2018 50 585 M
EBIT 2018 12 696 M
Net income 2018 8 373 M
Debt 2018 15 393 M
Yield 2018 3,46%
P/E ratio 2017 25,45
P/E ratio 2018 21,73
EV / Sales2017 4,97x
EV / Sales2018 4,75x
Capitalization 225 B
More Financials
Company
Novartis AG develops, manufactures, and markets healthcare products.It operates through the following segments: Pharmaceuticals, Alcon, Sandoz, and Corporate Activities.The Pharmaceuticals segment provides patent-protected prescription medicines.The Alcon segment offers surgical, ophthalmic... 
Sector
Pharmaceuticals
Calendar
10/24Earnings Release
More about the company
Surperformance© ratings of Novartis
Trading Rating : Investor Rating :
More Ratings
Latest news on NOVARTIS
10/19 NOVARTIS : Recent Findings from Novartis Provide New Insights into Glucosyltrans..
10/19 GILEAD SCIENCES : 2nd gene therapy for blood cancer approved
10/19 NOVARTIS : Drug Revolade(R) Shows Long-Term Disease Control for Chronic/Persiste..
10/19 NOVARTIS : sheds generics plant and 450 jobs amid pricing pressure
10/19 NOVARTIS : FDA OKs 2nd gene therapy for blood cancer; 1st for adults
10/18 NOVARTIS : 450 jobs to go as pricing pressures push Novartis to close CO generic..
10/18 NOVARTIS : drug Revolade® shows long-term disease control for chronic/persistent..
10/13 NOVARTIS : Alcon Laboratories, Inc. Constellation LXT Vitrectomy/ Vitreoretinal ..
10/13 NOVARTIS : 65-- Alcon Laboratories, Inc. Constellation LXT Vitrectomy/ Vitreoret..
10/13 NOVARTIS AG (ADR)(NYSE : NVS) Says It Will Not Sell Its Stake In Roche
More news
Sector news : Pharmaceuticals - NEC
04:15p Bank, tech stocks lift Wall Street
11:45aDJABBOTT LABORATORIES : Hacking Is a Risk for Pacemakers. So Is the Fix
10/19DJCELGENE : Halts Crohn's Disease Drug Trials
10/19DJEuropean Corporate Roundup for Thursday
10/19DJEuropean Corporate Roundup for Thursday
More sector news : Pharmaceuticals - NEC
4-Traders Strategies on NOVARTIS 
NOVARTIS AG - 2016
A trend reversal can be anticipated
BUY
More Strategies
Latest Tweets
05:14pNovartis AG given CHF 88 PT by Morgan Stanley. buy rating.  
05:14pRoche Holding given CHF 260 PT by Morgan Stanley. neutral rating.  
03:53pNovartis partner Durect registers a PhIII pain drug flop, biotech’s shares cr..
3
03:14pRoche Holding given CHF 254 PT by Deutsche Bank AG. neutral rating.  
03:14pRoche Holding given CHF 226 PT by Kepler Capital Markets. neutral rating.  
More tweets
Qtime:264
News from SeekingAlpha
04:16a Tracking Ken Fisher's Fisher Asset Management Portfolio - Q3 2017 Update
10/19 BIOTECH FORUM DAILY DIGEST : Spotlighting Ignyta's Big Recent Rally
10/19 What 'Yes' For Its CAR-T Therapy May Mean For Gilead
10/19 YOUR DAILY PHARMA SCOOP : Gilead's Brave New World, AZN's Lynparza SNDA, RXDX En..
10/19 FDA Approval Of Gilead CAR-T Therapy Will Move The Needle
Chart NOVARTIS
Duration : Period :
Novartis Technical Analysis Chart | NOVN | CH0012005267 | 4-Traders
Technical analysis trends NOVARTIS
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 32
Average target price 87,4 $
Spread / Average Target 1,2%
EPS Revisions
Managers
NameTitle
Joseph Jimenez Chief Executive Officer
Hans Jörg Reinhardt Independent Non-Executive Chairman
Harry Kirsch Chief Financial Officer
Vasant Narasimhan Chief Medical Officer & Head-Drug Development
Srikant Madhav Datar Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
NOVARTIS13.50%226 453
JOHNSON & JOHNSON23.29%377 585
ROCHE HOLDING LTD.5.55%215 760
PFIZER11.58%213 372
MERCK AND COMPANY7.88%173 214
AMGEN27.41%135 924